Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval.
about
Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study.Trastuzumab: a review of its use in HER2-positive advanced gastric cancer.Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany.HER-2 Protein Overexpression in Patients with Gastric and Oesophageal Adenocarcinoma at a Tertiary Care Facility in Ghana.
P2860
Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Metastatic esophagogastric ade ...... r trastuzumab market approval.
@en
Metastatic esophagogastric ade ...... r trastuzumab market approval.
@nl
type
label
Metastatic esophagogastric ade ...... r trastuzumab market approval.
@en
Metastatic esophagogastric ade ...... r trastuzumab market approval.
@nl
prefLabel
Metastatic esophagogastric ade ...... r trastuzumab market approval.
@en
Metastatic esophagogastric ade ...... r trastuzumab market approval.
@nl
P2093
P2860
P1476
Metastatic esophagogastric ade ...... r trastuzumab market approval.
@en
P2093
Ali-Nuri Hünerlitürkoglu
Deniz Gencer
Harald Scheiber
Iris Burkholder
Lenka Kellermann
Michael Gonnermann
Ralf-Dieter Hofheinz
Reyad Dada
Salah-Eddin Al-Batran
Thomas Kegel
P2860
P2888
P304
P356
10.1007/S00432-012-1335-7
P577
2012-10-19T00:00:00Z